Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Account Payables (2016 - 2022)

Abeona Therapeutics (ABEO) has 6 years of Change in Account Payables data on record, last reported at -$296000.0 in Q1 2022.

  • For Q1 2022, Change in Account Payables fell 120.86% year-over-year to -$296000.0; the TTM value through Jun 2022 reached -$19.6 million, down 372.82%, while the annual FY2024 figure was -$5.0 million, N/A changed from the prior year.
  • Change in Account Payables reached -$296000.0 in Q1 2022 per ABEO's latest filing, up from -$20.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.5 million in Q3 2018 and bottomed at -$20.0 million in Q4 2021.
  • Average Change in Account Payables over 3 years is -$1.0 million, with a median of $669000.0 recorded in 2021.
  • The widest YoY moves for Change in Account Payables: up 387.85% in 2018, down 176.69% in 2018.
  • A 3-year view of Change in Account Payables shows it stood at -$273000.0 in 2018, then crashed by 7226.01% to -$20.0 million in 2021, then skyrocketed by 98.52% to -$296000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$296000.0 in Q1 2022, -$20.0 million in Q4 2021, and $669000.0 in Q3 2021.